199 related articles for article (PubMed ID: 37044092)
61. High Concentration of Dezocine Induces Immune Escape of Lung Cancer and Promotes Glucose Metabolism through Up-Regulating PD-L1 and Activating the NF-κB Pathway.
Dong W; Zhang D; Zhu A; Hu Y; Li W
Curr Mol Med; 2022; 22(10):919-928. PubMed ID: 34951362
[TBL] [Abstract][Full Text] [Related]
62. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
63. Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8
Wang CI; Chang YF; Sie ZL; Ho AS; Chang JS; Peng CL; Cheng CC
Cells; 2021 Sep; 10(10):. PubMed ID: 34685495
[TBL] [Abstract][Full Text] [Related]
64. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Villaruz LC; Socinski MA
Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
[TBL] [Abstract][Full Text] [Related]
65. Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells.
Shwe TH; Pothacharoen P; Phitak T; Wudtiwai B; Kongtawelert P
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445462
[TBL] [Abstract][Full Text] [Related]
66. Analysis of programmed death-ligand 1 expression in primary normal human dermal fibroblasts after DNA damage.
Hagiwara Y; Sato H; Permata TBM; Niimi A; Yamauchi M; Oike T; Nakano T; Shibata A
Hum Immunol; 2018 Aug; 79(8):627-631. PubMed ID: 29859207
[TBL] [Abstract][Full Text] [Related]
67. Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Clin Cancer Res; 2016 May; 22(10):2329-34. PubMed ID: 27016309
[TBL] [Abstract][Full Text] [Related]
68. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
69. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.
Rivera N; Boada A; Bielsa MI; Fernández-Figueras MT; Carcereny E; Moran MT; Ferrándiz C
JAMA Dermatol; 2017 Nov; 153(11):1162-1165. PubMed ID: 28700789
[TBL] [Abstract][Full Text] [Related]
70. Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
Hu W; Ma Y; Zhao C; Yin S; Hu H
Mol Carcinog; 2021 Nov; 60(11):746-757. PubMed ID: 34411338
[TBL] [Abstract][Full Text] [Related]
71. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
Wu Q; Zhao Y; Sun Y; Yan X; Wang P
Oncol Rep; 2018 Mar; 39(3):1461-1468. PubMed ID: 29328389
[TBL] [Abstract][Full Text] [Related]
72. Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer.
Ma Y; Marinkova R; Nenkov M; Jin L; Huber O; Sonnemann J; Peca N; Gaßler N; Chen Y
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232331
[TBL] [Abstract][Full Text] [Related]
73. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
74. Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer.
Hogg SJ; Motorna O; Kearney CJ; Derrick EB; House IG; Todorovski I; Kelly MJ; Zethoven M; Bromberg KD; Lai A; Beavis PA; Shortt J; Johnstone RW; Vervoort SJ
Clin Epigenetics; 2022 Jul; 14(1):96. PubMed ID: 35902886
[TBL] [Abstract][Full Text] [Related]
75. Upregulation of PD-L1 in Senescence and Aging.
Onorati A; Havas AP; Lin B; Rajagopal J; Sen P; Adams PD; Dou Z
Mol Cell Biol; 2022 Oct; 42(10):e0017122. PubMed ID: 36154662
[TBL] [Abstract][Full Text] [Related]
76. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
77. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
78. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
Lai Q; Wang H; Li A; Xu Y; Tang L; Chen Q; Zhang C; Gao Y; Song J; Du Z
Oncogene; 2018 Apr; 37(17):2302-2312. PubMed ID: 29422611
[TBL] [Abstract][Full Text] [Related]
79. Tofacitinib overcomes an IFNγ-induced decrease in NK cell-mediated cytotoxicity via the regulation of immune-related molecules in LC-2/ad.
Okita R; Shimizu K; Nojima Y; Saisho S; Nakata M
Thorac Cancer; 2021 Mar; 12(6):775-782. PubMed ID: 33491334
[TBL] [Abstract][Full Text] [Related]
80. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Luo N; Formisano L; Gonzalez-Ericsson PI; Sanchez V; Dean PT; Opalenik SR; Sanders ME; Cook RS; Arteaga CL; Johnson DB; Balko JM
Oncoimmunology; 2018; 7(6):e1438106. PubMed ID: 29872580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
